Testimonials Do Not Convert Patients from Brand to Generic Medication

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11920070">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11920070</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP</a></td>
</tr>
</tbody>
</table>
Testimonials Do Not Convert Patients from Brand to Generic Medication

John Beshears, Ph.D.,
Stanford University, National Bureau of Economic Research Graduate School of Business,
Stanford University, 655 Knight Way, Stanford, CA 94305-7298

James J. Choi, Ph.D.,
Yale University, National Bureau of Economic Research Yale School of Management, 135
Prospect Street, P.O. Box 208200, New Haven, CT 06520-8200

David Laibson, Ph.D.,
Harvard University, National Bureau of Economic Research Harvard University, Littauer Center
M-12, Cambridge, MA, 02138

Brigitte C. Madrian, Ph.D., and
Harvard University, National Bureau of Economic Research John F. Kennedy School of
Government, Mailbox 114, 79 JFK Street, Cambridge, MA 02138

Gwendolyn Reynolds, M.T.S
National Bureau of Economic Research National Bureau of Economic Research, 1050
Massachusetts Ave, Cambridge, MA 02138

Abstract

Objectives—To assess whether the addition of a peer testimonial to an informational mailing increases conversion rates from brand-name prescription medications to lower-cost therapeutic equivalents, and whether the testimonial’s efficacy increases when information is added about an affiliation the quoted individual shares with the recipient.

Research Design and Methods—5,498 union members were randomly assigned to receive one of three different informational letters: one without a testimonial (No Testimonial Group), one with a testimonial from a person whose shared union affiliation with the recipient was not disclosed (Unaffiliated Testimonial Group), and one with a testimonial from a person whose shared union affiliation with the recipient was disclosed (Affiliated Testimonial Group).

Results—The conversion rate for the No Testimonial Group was 12.2%, which is higher than the Unaffiliated Testimonial Group rate of 11.3% and the Affiliated Testimonial Group rate of 11.7%. The differences between the groups are not statistically significant.

Conclusions—Short peer testimonials do not increase the impact of a mailed communication on conversion rates to lower-cost, therapeutically equivalent medications, even when the testimonial is presented as coming from a more socially proximate peer.

Keywords
Testimonial; peer information; social proximity; communication; generic medication
Saez; Sacerdote), and studies show that the influence of a peer is increasing in the peer’s social proximity (Christakis and Fowler; Hoxby; Soetevent and Kooreman).

We conducted a randomized controlled trial to assess whether adding a peer testimonial to a mailing increases conversions from brand-name prescription medications to lower-cost equivalents. In coordination with a pharmacy benefit manager (PBM), 5,498 union members were randomly assigned to receive one of three informational letters. Members were selected for the study if they had, in the six months prior to May 2011, filled a brand name prescription that had a cheaper therapeutic equivalent.

Members in the No Testimonial Group received a letter listing cheaper therapeutic equivalents available for the recipient’s brand name prescription medication and the associated cost savings to the recipient from switching to each of these alternatives. Members in the Unaffiliated Testimonial Group received a letter identical to the No Testimonial letter except for the addition of the following testimonial from a member of their union: “Switching to a lower-cost generic medication puts money back in my pocket every month.” Beneath the testimonial appeared the quoted member’s first name, last initial, city, and state. Members in the Affiliated Testimonial Group received a letter identical to the Unaffiliated Testimonial letter except for the addition of the quoted member’s union affiliation below the testimonial.

The letters were sent on May 1, 2011. The PBM measured the targeted members’ prescription drug claims for six months after the mailing.

The conversion rate to lower-cost alternatives for the No Testimonial Group was 12.2%, which is higher than the Unaffiliated Testimonial Group rate of 11.3% and the Affiliated Testimonial Group rate of 11.7%. The differences in the conversion rate between the control and the treatment groups are not statistically significant, and adding demographic controls does not change the significance or the rank order of the groups’ conversion rates (Table 1, columns 1–3).

The differences between the control and the treatment groups in the percent of employees who converted to a cheaper alternative and never reconverted to the brand name are also not statistically significant, and including demographic controls does not change their significance (Table 1, columns 4–6).

In conclusion, we find that adding a short peer testimonial to a letter about the benefits of generic drugs did not increase the likelihood of the recipient converting to a lower-cost therapeutic alternative, even when the testimonial was marked as coming from a member of the recipient’s union. These results suggest that organizations need not expend the considerable effort required to solicit short testimonials from peers of their health communication recipients.

Acknowledgments

We thank Express Scripts for collaborating on the design of the mailing, conducting the field experiment, and providing the data. We thank Luca Maini, Christopher Clayton, John Klopfier, and Michael Puempel for excellent research assistance. We acknowledge individual and collective financial support from National Institutes of Health grants P30-AG-034532, R01-AG-021650, and P01-AG-005842.

References


Table 1

Conversion Rate to Cheaper Therapeutically Equivalent Alternatives

<table>
<thead>
<tr>
<th></th>
<th>Dependent variable: Converted to Cheaper Alternative</th>
<th>Dependent variable: Converted to Alternative and Did Not Reconvert in the Six Month Follow-up Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1)</td>
<td>(2)</td>
</tr>
<tr>
<td>Unaffiliated Testimonial Group</td>
<td>−0.865 (1.059)</td>
<td>−0.726 (1.097)</td>
</tr>
<tr>
<td>Affiliated Testimonial Group</td>
<td>−0.501 (1.061)</td>
<td>−0.561 (1.098)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>0.057 (0.042)</td>
<td>0.069 (0.044)</td>
</tr>
<tr>
<td>Female</td>
<td>−0.832 (0.902)</td>
<td>−0.925 (0.903)</td>
</tr>
<tr>
<td>Number of Family Members Covered by Rx Drug Plan</td>
<td>0.098 (0.336)</td>
<td>0.046 (0.343)</td>
</tr>
<tr>
<td>Constant</td>
<td>12.165** (0.745)</td>
<td>9.269** (2.757)</td>
</tr>
<tr>
<td>Demographic Control Variables from Outside Marketing Firm</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Observations</td>
<td>5,498</td>
<td>5,078</td>
</tr>
<tr>
<td>R²</td>
<td>0.000</td>
<td>0.001</td>
</tr>
</tbody>
</table>

This table shows OLS linear probability regression results. Standard errors are in parentheses. Statistical significance at the 5% and 1% level are indicated by * and **, respectively. When adding demographic controls, the sample size falls due to missing values. The demographic control variables from an outside marketing firm are 24 indicators for membership in Nielsen Life Stage Groups and Nielsen Social Groups.